Mural Oncology plc (MURA) is experiencing a boost in its stock price following the company's announcement of significant advancements in its drug development pipeline. The company has reported progress in the trials of its investigational therapy, nemvaleukin, which is being tested for ovarian cancer and melanoma. Additionally, Mural Oncology has extended its cash runway into the first quarter of 2026, thanks to operational efficiencies. This financial extension, along with plans to nominate new drug candidates and submit an Investigational New Drug (IND) application for a phase 1 trial of MURA-8518 by the fourth quarter of 2025, has positioned the company as a promising player in the field of cancer treatment.
The current price of MURA stock is $3.75, reflecting a 2.74% increase from the previous close of $3.65. The stock opened at $3.90 and has seen a high of $4.00 and a low of $3.73 so far today. Despite being just half an hour into the trading day, the stock has already seen a volume of 255,267 shares, which is 151.99% of its average daily volume of 167,945 shares, indicating heightened interest and trading activity.